So who got the better deal here? Well to understand that we need to look at the background for each company and the deal justifications. Here is how Amgen described Onyx:
'Onyx Pharmaceuticals, Inc. is a global biopharmaceutical company engaged in the development and commercialization of innovative therapies for improving the lives of people with cancer. Onyx has an important and growing multiple myeloma franchise, with Kyprolis® (carfilzomib) for Injection already approved in
In terms of why Amgen would want to buy Onyx, here are some further extracts from the press release:
'Amgen is a global leader in oncology. As a focused oncology company, Onyx's products and pipeline strengthen
Clearly the Kyprolis product is all-important to Amgen:
'Onyx holds global rights to Kyprolis, excluding Japan. Kyprolis has an orphan drug designation in the U.S. with exclusivity until
Looking at the (secured) Onyx investor presentation, Kyprolis was all of the company's revenue growth during H1 2013, a period when - at the net level - the company was still loss-making.
On current projections, driven by Kyprolis, Onyx revenues should double from c. US$600m to US$1.2bn in a couple of years. You cannot argue against this, especially when Onyx reports a high 90% gross margin on the product. Exclusivity until 2019 and other patents until 2025 combined with scope to sell the treatment outside of the US adds up to a strong combination. But around US$10bn worth?
A slide (below) from Amgen's recent Q2 2013 corporate presentation can help us with a different insight. Amgen is a fine company...but is at that growth plateau where earnings are driven by cost cuts and a lower tax rates. Yes, they have a pipeline, but buying Onyx gives it a significant boost.
I think it is hard to say today whether Amgen have overpaid for Onyx today, although my instinct is that it is a full price. To make the deal work I think will require cost control and marketing skill - something which bigger cap pharmaceutical companies like Amgen do have. Rather than going potentially ex-growth, they have focused on buying growth which, at least in the short-term, the market generally likes. This is undoubtedly the major positive. And due to low gearing / low cost of borrowing the deal is quickly financially accretive (2015 as per the press release).
One final point. Amgen and other companies (supposedly including AstraZeneca) have been circling Onyx for a while. This report from a few weeks ago suggests that Amgen reduced their potential bid level due to data unavailability. It is unusual to see a recent share price like Onyx's where the bid level is not a new recent high of the share.


No comments:
Post a Comment